{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:10Z","timestamp":1793656510548,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10147-025-02946-4","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:11:51Z","timestamp":1767849111000},"page":"428-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed\/refractory large B cell lymphoma in Japan"],"prefix":"10.1007","volume":"31","author":[{"given":"Tetsuro","family":"Ochi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-8088","authenticated-orcid":false,"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiteru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"9","key":"2946_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842\u2013858","journal-title":"N Engl J Med"},{"issue":"16","key":"2946_CR2","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808","journal-title":"Blood"},{"issue":"15","key":"2946_CR3","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1002\/cam4.4062","volume":"10","author":"T Suzuki","year":"2021","unstructured":"Suzuki T, Maruyama D, Miyagi-Maeshima A et al (2021) Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. Cancer Med 10(15):5101\u20135109","journal-title":"Cancer Med"},{"issue":"5","key":"2946_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.bbmt.2011.10.010","volume":"18","author":"N Mounier","year":"2012","unstructured":"Mounier N, Canals C, Gisselbrecht C et al (2012) High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 18(5):788\u2013793","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2946_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/jnci\/djw257","volume":"108","author":"GS Nowakowski","year":"2016","unstructured":"Nowakowski GS, Blum KA, Kahl BS et al (2016) Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research. J Natl Cancer Inst 108(12):257","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2946_CR6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/cas.13239","volume":"108","author":"S Makita","year":"2017","unstructured":"Makita S, Yoshimura K, Tobinai K (2017) Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci 108(6):1109\u20131118","journal-title":"Cancer Sci"},{"issue":"26","key":"2946_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"issue":"1","key":"2946_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20(1):31\u201342","journal-title":"Lancet Oncol"},{"issue":"3","key":"2946_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12185-022-03494-7","volume":"117","author":"K Kato","year":"2023","unstructured":"Kato K, Fujii N, Makita S et al (2023) A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. Int J Hematol 117(3):409\u2013420","journal-title":"Int J Hematol"},{"issue":"1","key":"2946_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"9","key":"2946_CR11","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1007\/s10147-020-01699-6","volume":"25","author":"H Goto","year":"2020","unstructured":"Goto H, Makita S, Kato K et al (2020) Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed\/refractory diffuse large B-cell lymphoma. Int J Clin Oncol 25(9):1736\u20131743","journal-title":"Int J Clin Oncol"},{"issue":"10254","key":"2946_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852","journal-title":"Lancet"},{"issue":"24","key":"2946_CR13","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1002\/cam4.4820","volume":"11","author":"S Makita","year":"2022","unstructured":"Makita S, Yamamoto G, Maruyama D et al (2022) Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Cancer Med 11(24):4889\u20134899","journal-title":"Cancer Med"},{"issue":"10343","key":"2946_CR14","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J et al (2022) Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399(10343):2294\u20132308","journal-title":"Lancet"},{"issue":"14","key":"2946_CR15","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J et al (2023) Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141(14):1675\u20131684","journal-title":"Blood"},{"issue":"8","key":"2946_CR16","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA et al (2022) Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol 23(8):1066\u20131077","journal-title":"Lancet Oncol"},{"key":"2946_CR17","doi-asserted-by":"crossref","unstructured":"Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel for R\/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. Blood Adv. 2025 in press.","DOI":"10.1182\/bloodadvances.2024015262"},{"issue":"7","key":"2946_CR18","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748","journal-title":"Leukemia"},{"issue":"4","key":"2946_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2946_CR20","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra AJ et al (2019) Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(12):2305\u20132321","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2946_CR21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.bbmt.2020.04.008","volume":"26","author":"V Bachanova","year":"2020","unstructured":"Bachanova V, Bishop MR, Dahi P et al (2020) Chimeric antigen receptor T cell therapy during the COVID-19 pandemic. Biol Blood Marrow Transplant 26(7):1239\u20131246","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2946_CR22","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"6","key":"2946_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO et al (2014) Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging 41(6):1113\u20131122","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2946_CR24","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","volume":"9","author":"PA Riedell","year":"2025","unstructured":"Riedell PA, Grady CB, Nastoupil LJ et al (2025) Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv 9(5):1232\u20131241","journal-title":"Blood Adv"},{"issue":"5","key":"2946_CR25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41375-024-02213-x","volume":"38","author":"A Chiappella","year":"2024","unstructured":"Chiappella A, Casadei B, Chiusolo P et al (2024) Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia 38(5):1107\u20131114","journal-title":"Leukemia"},{"issue":"2","key":"2946_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70091","volume":"9","author":"J Galtier","year":"2025","unstructured":"Galtier J, Mesguich C, Sesques P et al (2025) <article-title update=\"added\">Outcomes of patients with relapsed or refractory primary mediastinal B\u2010cell lymphoma treated with anti\u2010CD19 CAR\u2010T cells: carthym, a study from the French national DESCAR\u2010T registry. Hemasphere 9(2):e70091","journal-title":"Hemasphere"},{"issue":"23","key":"2946_CR27","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1182\/blood.2024026831","volume":"145","author":"L Samples","year":"2025","unstructured":"Samples L, Sadrzadeh H, Frigault MJ et al (2025) Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood 145(23):2762\u20132767","journal-title":"Blood"},{"issue":"7","key":"2946_CR28","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.jtct.2023.03.019","volume":"29","author":"C De Philippis","year":"2023","unstructured":"De Philippis C, Mannina D, Giordano L et al (2023) Impact of preemptive use of tocilizumab on chimeric antigen receptor T cell outcomes in non-Hodgkin lymphoma. Transplant Cell Ther 29(7):429.e1-429.e6","journal-title":"Transplant Cell Ther"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02946-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02946-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02946-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:03:33Z","timestamp":1771952613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02946-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2946"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02946-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM received honoria for lectures from Chugai Pharmaceutical Co., Bristol Myers Squibb, Gilead Sciences and Genmab. SF received research funding from LOXO Oncology, AbbVie, Chugai Pharmaceutical Co. and Mitsubishi Tanabe Pharma Co. WM received research finding from Genmab, Nippon Shinyaku Co. and Ono Pharmaceutical Co. KI (Izutsu) received research funding from AstraZeneca, AbbVie, Incyte Biosciences Japan, Bristol Myers Squibb, Novartis, Daiichi Sankyo Co., Chugai Pharmaceutical Co., Beigene, Genmab, LOXO Oncology and Regeneron. No other authors declare conflicts of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Ethics Review Board of the National Cancer Center, Tokyo, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived because of the retrospective, observational nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}